Clinical Trial Update: Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics [Phase 1]

View source ↗

Summary

The study reports the completion of a Phase 1 safety, tolerability, and pharmacokinetics evaluation of ACP-104 in schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• ACP-104

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED